John Milligan (Insider Trades), CEO and president of Gilead Sciences Inc. (GILD), sold 112,000 company shares on July 5. The price per share was $84.33 for a total transaction of $9,444,960.
Gilead Sciences is a global biopharmaceutical company that discovers, develops and commercializes therapies for life-threatening disease. The company has a market cap of $113.83 billion and a P/S ratio of 3.48.
The number of insider sells increased from 52 transactions in 2013 to 84 transactions in 2014; however, the total volume of Gilead Sciences shares sold by insiders decreased from 6,778,547 to 4,203,426 in 2013 and 2014. Since 2013, there were only two insider buys of Gilead Sciences, each for 10,000 shares. Including the July 5 transaction, Milligan sold 2,231,142 shares of Gilead Sciences in 17 transactions since 2013. Another Gilead Sciences insider, Executive Chairman John Martin (Insider Trades), sold 100,000 shares on July 1 for a per share price of $84.73. 
The number of insider sells is directly related to the company’s month-end price; however, the volume of insider shares sold does not seem to follow the same trend. For more information about insider trades with Gilead Sciences, click here.
The company reported total revenue of $7.794 billion for the first quarter. Total revenue increased from $7.594 billion reported by Gilead Sciences in the previous first quarter. On the other hand, net income and earnings per share decreased from $4.333 billion, or $2.76 per share, to $3.566 billion, or $2.53 per share, when comparing the same time periods. Gilead Sciences' annual revenue and annual net income increased 39.56% and 59.03% since 2011.
On June 28, the company announced that the U.S. Food and Drug Administration (FDA) approved Epclusa, the first all-oral, pan-genotypic, single-tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.
Milligan commented that FDA approval of Epclusa “represents a significant advance for patients with HCV genotypes 2 and 3 who previously required more complex and costly regimens.” On June 20, the company announced data from four preclinical and Phase 1 studies evaluating bictegravir, and investigational once-daily integrase strand transfer inhibitor (INSTI) for the treatment of HIV-1 infection.
Norbert Bischofberger, executive vice president of Research and Development and chief scientific officer of Gilead Sciences, commented that the results from the first Phase 1 human trial of bictegravir “provided proof of concept for further evaluation of bictegravir as part of a single tablet regimen.” Bischofberger continued that the drug “represents Gilead’s ongoing efforts to develop new therapies with the potential to improve upon currently available treatments and address the unmet needs of people living with HIV.”
According to GuruFocus.com information, Gilead Sciences has a business predictability rank of 1 out of 5 stars. For more information about business predictability rank, click here.
David Dreman (Trades, Portfolio) and Joel Greenblatt (Trades, Portfolio) increased their stakes in Gilead Sciences while Jim Simons (Trades, Portfolio) reduced his stake in the company during the first quarter. Dreman acquired 23,210 shares at an average per share price of $90.37 after selling out 11,228 shares for an average per share price of $104.10 in the previous quarter. Greenblatt increased his stake in Gilead Sciences by 10.68%, purchasing 93,396 shares after decreasing his holding with the company by 6.70%, selling 62,736 shares in the previous quarter for an average per share price of $104.10. Simons reduced his holding by 68.79% in first quarter, after increasing it by 727.49% in the previous quarter. For more information about guru trades with Gilead Sciences, click here.
For more stock trades of gurus in real time, visit GuruFocus’ Real Time Picks, a Premium Feature.
Start a free seven-day trial of Premium Membership to GuruFocus.
